Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma

World J Clin Oncol. 2013 May 10;4(2):29-42. doi: 10.5306/wjco.v4.i2.29.


Non-small-cell lung cancer (NSCLC) remains the leading cause of cancer-related death in both men and women in the United States. Platinum-based doublet chemotherapy has been a standard for patients with advanced stage disease. Improvements in overall survival and quality of life have been modest. Improved knowledge of the aberrant molecular signaling pathways found in NSCLC has led to the development of biomarkers with associated targeted therapeutics, thus changing the treatment paradigm for many NSCLC patients. In this review, we present a summary of many of the currently investigated biologic targets in NSCLC, discuss their current clinical trial status, and also discuss the potential for development of other targeted agents.

Keywords: Anaplastic lymphoma kinase; BRAF; Epidermal growth factor receptor; Molecular targeted therapy; Non-small cell lung cancer; Tyrosine kinase inhibitors; Vascular endothelial growth factor.